ABS-201 SC Multiple Doses

Preclinical

ABS-201 SC Multiple Doses is one of 2 therapeutic programs targeting Androgenetic Alopecia (AGA). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Androgenetic Alopecia (AGA)Recruiting

Androgenetic Alopecia (AGA)Preclinical

Recruiting

Competition

Competitive Landscape

1 competitor in Androgenetic Alopecia (AGA)

#DrugCompanyPhaseTrials

VDPHL01

VVeradermics, Inc.

Phase 3

1 2

ABS-201 SC Multiple Doses

AAbsci Pty Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Androgenetic Alopecia (AGA)

NCT07317544

Clinical

Trials by Indication[1]

Androgenetic Alopecia (AGA)1 trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ABS-201 in Adult Participants With and Without Androgenetic Alopecia

Recruiting·AAbsci Pty Ltd.·Preclinical·NCT07317544·227 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ABS-201 SC Multiple Doses. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for ABS-201 SC Multiple Doses. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Absci Pty Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: AAbsci Pty Ltd.

ABS-201 SC Multiple Doses

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Androgenetic Alopecia (AGA)1 trial

References

Drug Info

Quick Facts

Related News